- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Polyrizon Marches on European Patent | - | Baystreet.ca | ||
| Mi | Polyrizon receives European patent application publication | 1 | Investing.com | ||
| Mi | Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology | 212 | GlobeNewswire (Europe) | Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| Mo | Polyrizon signs two more U.S. sites for allergy trial | 1 | Investing.com | ||
| Mo | Polyrizon Ltd.: Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX Trial | 1 | GlobeNewswire (USA) | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Fr | Polyrizon verlängert Exklusivitätsfrist für Übernahmegespräche mit Arrow Aviation | 1 | Investing.com Deutsch | ||
| Fr | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.05. | Polyrizon signs first clinical trial agreement for allergy drug | 1 | Investing.com | ||
| 13.05. | Polyrizon Ltd.: Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX Allergy Blocker Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 13.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.05. | Polyrizon submits amended claims for intranasal drug delivery patent | 1 | Investing.com | ||
| 04.05. | Polyrizon erweitert Patentansprüche für intranasale Wirkstoffplattform | 1 | Investing.com Deutsch | ||
| 04.05. | Polyrizon Ltd.: Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform | 155 | GlobeNewswire (Europe) | Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 04.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.04. | Polyrizon Ltd.: Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform | 380 | GlobeNewswire (Europe) | Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative... ► Artikel lesen | |
| 27.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Polyrizon Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 08.04. | Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements | 1 | GlobeNewswire (USA) | ||
| 08.04. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 5 Weiter >>
83 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 32,265 | +1,65 % | QIAGEN NV zündet Turbo - jetzt nicht den Einstieg verpassen! | ||
| NOVAVAX | 7,390 | -0,27 % | Novavax set for a seventh straight decline | ||
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 13,500 | -1,03 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,970 | +2,16 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,590 | +0,63 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| XOMA ROYALTY | 36,000 | 0,00 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,065 | +0,47 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| ORAGENICS | 6,000 | 0,00 % | Oragenics, Inc.: Oragenics Signs Letter of Intent to License CardioDialysis Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation | The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and... ► Artikel lesen | |
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 8,200 | -9,39 % | TENAX THERAPEUTICS, INC. - 8-K, Current Report | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | Unity Biotechnology, Inc. - 15-12G, Securities registration termination | ||
| SERES THERAPEUTICS | 5,600 | +0,18 % | Seres Therapeutics, Inc.: Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 | Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST net sales-based milestones Restructured lease materially reduces ongoing annual... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,315 (+2,85 %) liegt der Kurs bei 11,375 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.